Stable Mammalian Cell Lines for Unnatural Amino Acid Incorporation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing proteins with site-specific unnatural amino acids in mammalian cells face challenges in reproducibility and longevity, limiting their suitability for commercial-scale production due to transient transfection techniques and low protein titers.
Innovation Solution
Development of eukaryotic cell lines with stably integrated nucleic acid sequences encoding prokaryotic leucyl-tRNA synthetases and suppressor tRNAs, enabling the continuous expression of proteins containing unnatural amino acids for extended periods with high titers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transient transfection techniques are used to introduce engineered tRNA/aaRS pairs into expression host cells, then the ability to produce proteins with unnatural amino acids is achieved, but reproducibility and expression duration are limited
Solution Approach 1:
The invention performs preliminary action by stably integrating the engineered tRNA and aaRS genetic sequences into the genome of mammalian cells before protein expression. This stable integration ensures that the orthogonal translation system is permanently established in the cells, allowing for reproducible and long-term expression of proteins containing unnatural amino acids, thereby resolving the limitations of transient transfection methods
Solution Approach 2:
The invention changes the parameter of genetic sequence stability by transitioning from transient plasmid-based expression to stable genomic integration. This parameter change enables the expression system to maintain functionality over extended periods and across multiple cell generations, directly addressing the reproducibility and duration limitations of transient transfection
2Quantity of substance
If transient transfection techniques are used, then protein expression with unnatural amino acids is achieved, but protein titers remain low
Solution Approach 1:
The invention performs preliminary action by establishing stable cell lines with integrated orthogonal translation systems before scaling up production. This preliminary stabilization allows cells to be cultured and expanded to high densities while maintaining consistent expression of the engineered components, thereby enabling high protein titers and scalable manufacturing that transient methods cannot achieve
3Manufacturing precision
If engineered orthogonal tRNA/aaRS pairs are introduced into mammalian cells, then site-specific incorporation of unnatural amino acids is achieved, but the system lacks stability for commercial production
Solution Approach 1:
The invention merges the engineered orthogonal tRNA and aaRS components into a single stable genomic integration system in mammalian cells. This merging ensures that both components are co-expressed at appropriate levels and maintained together through cell divisions, providing the system stability required for commercial production while preserving the precise site-specific incorporation capability of the orthogonal pair
Data Source
AI summary
The invention relates generally to engineered tRNAs, engineered aminoacyl-tRNA synthetases, unnatural amino acids, and cells comprising the same, and their use in the incorporation of unnatural amino acids into proteins.